论文部分内容阅读
观察了编码人白细胞介素２（ＩＬ－２）基因的重组痘苗病毒（ｒｅｃｏｍｂｉｎａｎｔｖａｃｃｉｎｉａｖｉｒｕｓｅｎｃｏｄｉｎｇｈｕ－ｍａｎＩＬ－２ｇｅｎｅ，ＩＬ－２ＶＶ）对小鼠接种ＦＢＬ－３红白血病细胞诱发肿瘤的治疗作用。野生型ＦＢＬ－３红白血病细胞接种Ｃ５７ＢＬ／６小鼠皮下，建立荷瘤模型，随机分组，分别局部注射ＩＬ－２ＶＶ、ＴＫＶＶ、重组ＩＬ－２、Ｈａｎｋ＇ｓ液０．２ｍｌ／次，３／周，连续治疗２周。结果发现，小鼠局部注射ＩＬ－２ＶＶ组肿瘤出现晚，生长速度缓慢，生存期延长，与对照组相比，差异有非常显著性意义。进一步观察还发现ＩＬ－２ＶＶ能显著提高荷瘤小鼠脾细胞的自然杀伤细胞（ＮＫ）、细胞毒Ｔ淋巴细胞（ＣＴＬ）的活性，明显增强腹腔巨噬细胞杀伤活性，表明重组痘苗病毒介导的ＩＬ－２基因疗法能显著提高荷瘤小鼠的抗肿瘤免疫功能
To observe the therapeutic effect of recombinantvacciniavirusencodinghu-man IL-2gene (IL-2VV), a gene encoding human interleukin 2 (IL-2), on mice induced by FBL-3 erythroleukemia cells. The wild-type FBL-3 erythroleukemia cells were inoculated subcutaneously in C57BL / 6 mice to establish a tumor-bearing model. The models were randomly divided into 2 groups: IL-2VV, TKVV, recombinant IL- Week, continuous treatment for 2 weeks. The results showed that tumors in mice injected with IL-2VV late, slow growth, prolonged survival, compared with the control group, the difference was very significant. Further observation showed that IL-2VV could significantly increase the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL) in spleen cells of tumor-bearing mice and significantly increase the cytotoxic activity of peritoneal macrophages, indicating that recombinant vaccinia virus mediated IL-2 gene therapy can significantly improve anti-tumor immune function in tumor-bearing mice